CG
ATHE

Colony Group’s Alterity Therapeutics ATHE Stock Holding History

Colony Group’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-27
Closed -$1K – 269
2015
Q4 		$1K Hold
27
– – ﹤0.01% 720
2015
Q3 		$1K Hold
27
– – ﹤0.01% 787
2015
Q2 		$2K Hold
27
– – ﹤0.01% 683
2015
Q1 		$2K Hold
27
– – ﹤0.01% 670
2014
Q4 		$3K Hold
27
– – ﹤0.01% 680
2014
Q3 		$3K Hold
27
– – ﹤0.01% 731
2014
Q2 		$4K Hold
27
– – ﹤0.01% 625
2014
Q1 		$4K Hold
27
– – ﹤0.01% 683
2013
Q4 		$11K Buy
+27
New +$8.08K ﹤0.01% 474

Other funds holding ATHE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AIM
Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
MFS
MSI Financial Services Springfield, Massachusetts $3.07B AUM 10.22% 1-Year Est. Return

Colony Group's ATHE Position: Q1 2016 in Review

Colony Group sold out of Alterity Therapeutics (ATHE) in Q1 2016, closing a stake of 27 shares — an estimated $1K sold.

Colony Group first reported a position in ATHE in Q4 2013 and held it in 9 quarters. The position peaked at $11K in Q4 2013. 14 funds tracked by Wall St. Rank hold ATHE as of Q1 2016.

  • Colony Group reported no remaining Alterity Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Colony Group sold 27 Alterity Therapeutics shares in Q1 2016, an estimated $1K.
  • Colony Group first reported a position in Alterity Therapeutics in Q4 2013 and held it in 9 quarters.
  • Colony Group's Alterity Therapeutics position peaked at $11K in Q4 2013.
  • 14 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q1 2016.

Based on Colony Group's 13F filing for Q1 2016, filed 16 May 2016.